X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2588) 2588
female (2241) 2241
middle aged (1944) 1944
oncology (1634) 1634
adult (1629) 1629
aged (1595) 1595
epirubicin - administration & dosage (1548) 1548
antineoplastic combined chemotherapy protocols - therapeutic use (1393) 1393
epirubicin (1376) 1376
antineoplastic combined chemotherapy protocols - adverse effects (1225) 1225
chemotherapy (1130) 1130
male (1105) 1105
breast neoplasms - drug therapy (1104) 1104
epirubicin - adverse effects (999) 999
index medicus (932) 932
treatment outcome (765) 765
cancer (732) 732
doxorubicin (643) 643
breast cancer (638) 638
fluorouracil - administration & dosage (632) 632
cyclophosphamide - administration & dosage (606) 606
breast neoplasms - pathology (512) 512
drug administration schedule (472) 472
antineoplastic combined chemotherapy protocols - administration & dosage (469) 469
therapy (455) 455
cyclophosphamide (454) 454
cisplatin - administration & dosage (447) 447
anthracyclines (416) 416
disease-free survival (409) 409
epirubicin - therapeutic use (397) 397
neoplasm staging (395) 395
chemotherapy, adjuvant (369) 369
cisplatin (361) 361
cyclophosphamide - adverse effects (347) 347
paclitaxel (339) 339
docetaxel (332) 332
survival rate (326) 326
doxorubicin - adverse effects (323) 323
fluorouracil - adverse effects (313) 313
fluorouracil (311) 311
doxorubicin - administration & dosage (310) 310
carcinoma (307) 307
survival analysis (291) 291
paclitaxel - administration & dosage (289) 289
antibiotics, antineoplastic - adverse effects (287) 287
medicine & public health (283) 283
trial (282) 282
dose-response relationship, drug (279) 279
pharmacology & pharmacy (275) 275
antibiotics, antineoplastic - administration & dosage (267) 267
prospective studies (267) 267
follow-up studies (265) 265
survival (264) 264
care and treatment (263) 263
combined modality therapy (251) 251
prognosis (249) 249
aged, 80 and over (247) 247
adjuvant chemotherapy (235) 235
taxoids - administration & dosage (234) 234
retrospective studies (214) 214
neoplasm metastasis (213) 213
antineoplastic agents - adverse effects (211) 211
adenocarcinoma - drug therapy (208) 208
breast neoplasms - surgery (208) 208
stomach neoplasms - drug therapy (207) 207
deoxycytidine - analogs & derivatives (205) 205
research (205) 205
5-fluorouracil (203) 203
breast neoplasms - mortality (202) 202
adolescent (192) 192
toxicity (184) 184
analysis (183) 183
surgery (182) 182
combination (180) 180
cisplatin - adverse effects (175) 175
deoxycytidine - administration & dosage (175) 175
drug therapy (174) 174
neoadjuvant therapy (171) 171
risk factors (171) 171
infusions, intravenous (168) 168
time factors (168) 168
capecitabine (164) 164
cardiotoxicity (164) 164
neutropenia - chemically induced (164) 164
antibiotics, antineoplastic - therapeutic use (161) 161
adjuvant treatment (159) 159
antineoplastic agents - therapeutic use (159) 159
clinical trials (158) 158
health aspects (154) 154
doxorubicin - therapeutic use (151) 151
phase-ii (151) 151
methotrexate (150) 150
paclitaxel - adverse effects (149) 149
trastuzumab (148) 148
randomized-trial (147) 147
metastasis (146) 146
lung neoplasms - drug therapy (144) 144
antineoplastic agents - administration & dosage (142) 142
tumors (142) 142
neoadjuvant chemotherapy (141) 141
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2629) 2629
Japanese (80) 80
Chinese (40) 40
German (29) 29
French (24) 24
Spanish (14) 14
Italian (12) 12
Polish (7) 7
Bulgarian (4) 4
Hungarian (3) 3
Russian (3) 3
Danish (2) 2
Portuguese (2) 2
Czech (1) 1
Korean (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Wang, TW and Yuan, H and Diao, WL and Yang, R and Zhao, XZ and Guo, HQ
BMC UROLOGY, ISSN 1471-2490, 10/2019, Volume 19, Issue 1, pp. 1 - 5
Background Because of the failure, shortage and related toxicities of Bacillus Calmette-Guerin (BCG), the other intravesical chemotherapy drugs are also widely... 
UROLOGY & NEPHROLOGY | Intravesical therapy | Anthracycline antibiotics | Gemcitabine | NMIBC | IMMUNOTHERAPY | Data analysis | Statistical analysis | BCG | Radiation therapy | Cancer therapies | Bladder cancer | Patients | Urology | Chemotherapy | Hospitals | Anthracycline | Cellular biology | Antibiotics | Medical prognosis | Data collection | Epirubicin | Tumors
Journal Article
by Liu, TS and Qin, YR and Li, J and Xu, RH and Xu, JM and Yang, SJ and Qin, SK and Bai, YX and Wu, CP and Mao, YX and Wu, HY and Ge, YL and Shen, L
CANCER COMMUNICATIONS, ISSN 2523-3548, 06/2019, Volume 39, Issue 1, pp. 38 - 10
Background: The JACOB trial (NCT01774786) was a double-blinded, placebo-controlled, randomized, multicenter, international, phase III trial evaluating the... 
Gastroesophageal junction cancer | OXALIPLATIN | CAPECITABINE | Chemotherapy | EPIRUBICIN | Pertuzumab | ONCOLOGY | China | DOUBLE-BLIND | Safety | HER2 | Overall survival | 1ST-LINE THERAPY | Gastric cancer | Progression-free survival | Trastuzumab | Medical prognosis | Metastasis | Medical screening | Stomach cancer | Cancer therapies | Investigations | Tumors
Journal Article
by Xu, N and Hua, ZY and Ba, G and Zhang, SM and Liu, ZH and Thiele, CJ and Li, ZJ
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, ISSN 1756-9966, 03/2019, Volume 38, Issue 1, pp. 118 - 118
Journal Article
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 11/2019, Volume 863, p. 172703
Intravesical treatment of superficial bladder cancer with epirubicin is associated with local urological adverse effects, the causes of which are unknown. Our... 
Inflammation | Epirubicin | Adverse effects | Bladder cancer | Intravesical chemotherapy | Urothelium | BLADDER-CANCER | URINARY-BLADDER | CYCLOPHOSPHAMIDE-INDUCED CYSTITIS | MITOMYCIN-C | DOXORUBICIN | INTERLEUKIN-8 | THERAPY | NITRIC-OXIDE | PHARMACOLOGY & PHARMACY | EXPRESSION | ADENOSINE-TRIPHOSPHATE RELEASE
Journal Article
European Journal of Cancer, ISSN 0959-8049, 11/2019, Volume 121, pp. 40 - 47
Sex contributes to interpatient variability of chemotherapy metabolism and dose response, potentially influencing both efficacy and toxicity; however,... 
Chemotherapy | Toxicity | Oesophageal | Sex | Gastric | Survival | Cancer | PERIOPERATIVE CHEMOTHERAPY | PHASE-III | FLUOROURACIL | CAPECITABINE | EPIRUBICIN | CISPLATIN | PHARMACOKINETICS | ONCOLOGY | GASTRIC-CANCER | EPIDEMIOLOGY | Complications and side effects | Patient education | Analysis | Oncology, Experimental | Research
Journal Article
Clinical Genitourinary Cancer, ISSN 1558-7673, 10/2019, Volume 17, Issue 5, pp. e1003 - e1010
Non–muscle-invasive bladder cancer (NMIBC) can be treated using transurethral resection (TUR), but high incidence of intravesical recurrence remains a clinical... 
Intravesical recurrence | Prevention | Transurethral resection | Epirubicin | BCG | BACILLUS-CALMETTE-GUERIN | GUIDELINES | RISK | TUMORS | ONCOLOGY | UROLOGY & NEPHROLOGY | RECURRENCE | CARCINOMA | INTRAVESICAL EPIRUBICIN | Usage | Chemotherapy | BCG vaccines | Drug therapy | Bladder cancer | Risk factors | Cancer
Journal Article
European Journal of Obstetrics & Gynecology and Reproductive Biology, ISSN 0301-2115, 10/2019, Volume 241, pp. 49 - 55
Breast cancer patients often benefit from adjuvant chemotherapy, a protocol whose effectiveness is accompanied by disabling adverse effects. The aim of this... 
Adjuvant chemotherapy | Breast cancer | Nausea and vomiting | Constipation | Osteopathy | Quality of life | INDUCED NAUSEA | TRIALS | PROGNOSTIC-FACTORS | PREVENTION | FOLLOW-UP | COMMON TERMINOLOGY CRITERIA | OBSTETRICS & GYNECOLOGY | REPRODUCTIVE BIOLOGY | EPIRUBICIN | QUALITY-OF-LIFE | ADVERSE EVENTS
Journal Article
Journal of Advanced Medical and Dental Sciences Research, 09/2019, Volume 7, Issue 9, pp. 85 - 89
Background: Breast cancer is common in females and its treatment with chemotherapeutic agents is not free from hematological toxicity. There are many agents to... 
Blood transfusions | Tablets | Toxicity | Iron | Blood transfusion | Cancer therapies | Doxorubicin | Blood platelets | Cell cycle | Hemoglobin | Epirubicin | Drug dosages | Hematology | Anemia | Breast cancer | Grasses | Patients | Vitamins | Herbal medicine | Cyclophosphamide | Chemotherapy | Hospitals | Deterioration | Comparative studies | Breast | Platelets | Females | Wheat
Journal Article
ONCOLOGY NURSING FORUM, ISSN 0190-535X, 09/2019, Volume 46, Issue 5, pp. E145 - E158
PROBLEM IDENTIFICATION: This review identifies specific cardiotoxicity related to anthracycline chemotherapy, specific risk factors related to increased... 
ADJUVANT CHEMOTHERAPY | TRASTUZUMAB | NURSING | HEART-FAILURE | DOXORUBICIN | breast cancer | CARDIAC DYSFUNCTION | FOLLOW-UP | RISK | SYSTOLIC FUNCTION | cardiotoxicity | EPIRUBICIN | anthracycline | ONCOLOGY | survivors | ECHOCARDIOGRAPHY | Index Medicus | Nursing
Journal Article